Acute renal failure in acquired haemophilia following the use of high dose intravenous immunoglobulin.
High dose intravenous immunoglobulin (IVIG) is a useful form of treatment in patients with acquired haemophilia, a rare bleeding disorder due to auto-antibodies to factor VIII. We describe a patient with acquired haemophilia who developed acute renal failure rapidly after treatment with a high sucrose content IVIG preparation. We speculate that the sucrose content of the preparation was responsible for the renal failure and make recommendations on the use of IVIG in patients with acquired haemophilia.
Laidlaw
S
S
Sheffield Haemophilia and Thrombosis Centre, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF.
Bainton
R
R
Wilkie
M
M
Makris
M
M
D058186:Acute Kidney Injury / Q000139:chemically induced / Q000209:etiology*; D001323:Autoantibodies / Q000097:blood; D003920:Diabetes Mellitus; D005169:Factor VIII / Q000276:immunology / Q000378:metabolism; D006467:Hemophilia A / Q000150:complications* / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D013395:Sucrose / Q000009:adverse effects
D001323:Autoantibodies; D016756:Immunoglobulins, Intravenous; D013395:Sucrose; D005169:Factor VIII